Endotronix raises $32M in Series C

What does Endotronix do?
Endotronix, is a digital health medtech company which provides innovative solutions for patients with advanced heart failure. The company develops miniature, wireless and implantable pressure sensors which are implanted as a part of inventional cardiovascular procedures. The company’s solution combines a implantable pulmonary artery sensor and cloud based patient management system to improve OP blood management. Real time pulmonary artery pressures monitoring has been shown for reducing hospitalizations because of heart failure by as much as thirty seven percent. The company’s wireless solution integrates seamlessly the daily clinical monitoring of important physiological data with enhanced communications between caregivers, patients and clinicians for early detection of the worsening cardiac failure. Their protocol driven care management system aims in improving the life quality of million of patients suffering from advanced cardiac failure.

How much Endotronix was funded?
The company raised $32M in Series C on July 14, 2016 from OSF Ventures, Lumira Capital, Aperture Venture Partners, Bioventures Investors and SV Life Sciences.

Previous funding
$250k on October 8, 2010 from JumpStart Inc.
$1.8M on August 27, 2012
$1.19M on June 12, 2013
$1.6M in undisclosed round on April 29, 2014
$2.2M on February 13, 2015
$2.96M on December 30, 2015
What is next for Endotronix?
The company is well positioned to disrupt costly heart failure treatment patterns and add significant value to the market. The company is planning to use the latest funding for funding its clinical program including the commercialization of its cloud based outpatient management systems and study of its implantable wireless pulmonary artery sensor.

More about Endotronix

Endotronix was founded in 2007 by Anthony I. Nunez and Harry D. Rowland. It has its headquarters in East Peoria, Illinois.